PI4K2B

Across TCGA pan-cancer cohorts, PI4K2B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PI4K2B data layer compared with 26 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher PI4K2B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PI4K2B expression acts as an unfavorable survival marker.

BLCA, UCEC, and COAD are the cancer types where PI4K2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	All	0.100	0.626	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	OS	Median	III,IV	0.527	0.792	.012	6	view →
SKCM	OS	Median	II,III,IV	0.179	0.731	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PI4K2B–BLCA (DFS)

Open the BLCA breakdown →